Antiangiogenic treatment in metastatic urothelial cancer
Mené sur 41 patients atteints d'un cancer urothélial de stade avancé réfractaire à un traitement aux sels de platine, cet essai de phase II évalue l'activité et la toxicité du pazopanib, un médicament doté de propriétés antiangiogéniques
Advances in the treatment of metastatic urothelial cancer have been elusive for several decades. However, more than 30 years ago, Chodak and colleagues showed that the urine of patients with urothelial cancer contains proangiogenic substances. Other investigators have subsequently shown that various measures of angiogenesis, such as increased microvessel density, correlate with poor outcomes in patients with urothelial cancer. Disruption of the VEGFR pathway confers antitumour activity in bladder cancer cell lines and xenografts and concomitantly targeting VEGF receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) results in synergistic antitumour activity in models of tumour angiogenesis. Together, these findings have lent support to the clinical development of antiangiogenic approaches for the treatment of patients with metastatic urothelial cancer...
The Lancet Oncology , commentaire en libre accès, 2011